Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 107 publications
Combined FAK and MEK inhibition suppresses chromosome 8 gain malignant peripheral nerve sheath tumors.
Journal: The Journal of clinical investigation
Published: August 11, 2026
A Framework for Prioritizing Novel Agents in Malignant Peripheral Nerve Sheath Tumor Trials: A report from the Neurofibromatosis Clinical Trials Consortium.
Journal: Neuro-oncology
Published: May 13, 2026
BRAF V600E-mutated metastatic Wilms tumor with complete response to targeted RAF/MEK inhibition: a post-treatment follow-up case report.
Journal: Frontiers in oncology
Published: February 27, 2026
Outcomes Associated with Radiation Therapy for Localized Resectable Malignant Peripheral Nerve Sheath Tumors.
Journal: Advances in radiation oncology
Published: October 31, 2025
The effects of postoperative neurological deficits on overall survival in patients with malignant peripheral nerve sheath tumors.
Journal: Journal of neurosurgery. Spine
Published: September 07, 2025
Combined inhibition of SHP2 overcomes adaptive resistance to type 1 BRAF inhibitors in BRAF V600E-driven high-grade glioma.
Journal: Neuro-oncology advances
Published: September 03, 2025
Imaging features and the role of image-guided biopsy for assessment of premalignant versus malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Journal: Neuro-oncology practice
Published: August 19, 2025
SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 01, 2025
SARC031: A Phase 2 Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 01, 2025
Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma.
Journal: Cancer research
Published: July 14, 2025
Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma.
Journal: Cancer research
Published: July 14, 2025
Last Updated: 09/26/2026